%20-%2050mg?unique=6ac6667)
Ridaforolimus (Deforolimus, MK-8669) - 50mg
Ridaforolimus is an investigational small-molecule inhibitor specifically targeting mTOR, a key protein that regulates critical cellular processes, including protein synthesis, cell proliferation, cell cycle progression, and survival. mTOR integrates signals from proteins such as PI3K, AKT, and PTEN, which are often implicated in cancer development and progression.
By inhibiting mTOR, this compound induces a starvation-like state in cancer cells, disrupting essential processes such as growth, division, metabolism, and angiogenesis, thereby impairing tumor survival and progression.
This content will be shared across all product pages.
Chemical Details:
Molecular Formula: C₅₃H₈₄NO₁₄P
Molecular Weight: 1,013.2 g/mol
Chemical Structure:
Features a macrocyclic lactone ring characteristic of rapalogs.
Contains a phosphinate group enhancing its solubility and bioavailability.
Mechanism of Action:
Ridaforolimus binds to the FKBP12 protein, forming a complex that inhibits mTORC1 activity. This disruption halts key processes in tumor cells, including protein synthesis, angiogenesis, and metabolic adaptation, while promoting apoptosis in cancerous tissues.
Ridaforolimus is widely utilized in preclinical and clinical research to explore novel cancer therapies, particularly in malignancies driven by dysregulated mTOR signaling.
Note: For research use only. Not approved for diagnostic or therapeutic purposes.